Can vaccination roll-out be more equitable if population risk is taken into account?

PLoS One. 2021 Nov 15;16(11):e0259990. doi: 10.1371/journal.pone.0259990. eCollection 2021.

Abstract

Background: COVID-19 vaccination in many countries, including England, has been prioritised primarily by age. However, people of the same age can have very different health statuses. Frailty is a commonly used metric of health and has been found to be more strongly associated with mortality than age among COVID-19 inpatients.

Methods: We compared the number of first vaccine doses administered across the 135 NHS Clinical Commissioning Groups (CCGs) of England to both the over 50 population and the estimated frail population in each area. Area-based frailty estimates were generated using the English Longitudinal Survey of Ageing (ELSA), a national survey of older people. We also compared the number of doses to the number of people with other risk factors associated with COVID-19: atrial fibrillation, chronic kidney disease, diabetes, learning disabilities, obesity and smoking status.

Results: We estimate that after 79 days of the vaccine program, across all Clinical Commissioning Group areas, the number of people who received a first vaccine per frail person ranged from 4.4 (95% CI 4.0-4.8) and 20.1 (95% CI 18.3-21.9). The prevalences of other risk factors were also poorly associated with the prevalence of vaccination across England.

Conclusions: Vaccination with age-based priority created area-based inequities in the number of doses administered relative to the number of people who are frail or have other risk factors associated with COVID-19. As frailty has previously been found to be more strongly associated with mortality than age for COVID-19 inpatients, an age-based priority system may increase the risk of mortality in some areas during the vaccine roll-out period. Authorities planning COVID-19 vaccination programmes should consider the disadvantages of an age-based priority system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 / epidemiology
  • COVID-19 / immunology
  • COVID-19 Vaccines / immunology*
  • Dose-Response Relationship, Immunologic
  • England / epidemiology
  • Geography
  • Humans
  • Prevalence
  • Risk Factors
  • Vaccination*

Substances

  • COVID-19 Vaccines

Grants and funding

DSi, AM CW and FM are funded by the National Institute for Health Research Policy Research Unit in Older People and Frailty (PR-PRU-1217-21502). DSi, CW and FM are also funded by the Integrated Covid Hub North East. DSt is funded by NIHR School for Primary Care Research (SPCR-PDF-2020-161). The views expressed are those of the author(s) and not necessarily those of of the NIHR, the Department of Health and Social Care, or the Integrated Covid Hub North East.